Overview

Study to Evaluate Safety and Pharmacokinetics of GS-4059 (Tirabrutinib) in Healthy Volunteers and Participants With Rheumatoid Arthritis (RA)

Status:
Completed

Trial end date:
2016-09-01

Target enrollment:

Participant gender:

Summary

This study will consist of two parts: Part A will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of tirabrutinib in healthy participants. Part B will evaluate the safety, tolerability, and the effect of tirabrutinib on disease-specific clinical markers and outcomes in participants with rheumatoid arthritis (RA).

Phase:

Phase 1

Details

Lead Sponsor:

Gilead Sciences

Collaborator:

Ono Pharmaceutical Co. Ltd